Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures

Status Completed

Clinical Trial Summary

Specific Aim 1: To describe the adequacy of sedation associated with different regimens of IN DEX in children undergoing non-painful procedures. This aim will test the working hypothesis that IN DEX regimens are effective for producing sedation adequate for completion of non-painful procedures in children. Specific Aim 2: To describe the temporal characteristics associated with varied regimens of IN DEX in children undergoing non-painful procedures, such as time to onset of adequate sedation; time to procedure start; and time from procedure end to meeting discharge criteria. This aim will test the working hypothesis that IN DEX regimens have temporal characteristics that are favourable for sedating children for non-painful procedures. Specific Aim 3: To describe the adverse events associated with varied regimens of IN DEX in children undergoing non-painful procedures. This aim will test the working hypothesis that IN DEX regimens have a low incidence of adverse events.

Clinical Trial Description

Dexmedetomidine (DEX) is an alpha-2 receptor agonist with sedative, anxiolytic, and analgesics properties. DEX has been used extensively for sedation in children to facilitate different non-painful procedures, such magnetic resonance imaging (MRI), auditory brainstem response (ABR) tests, and computed tomography (CT) scans. In particular, DEX can be administered by the intranasal (IN) route. Intranasal administration has the benefits of being both effective and needle-free, of which the latter makes it less distressing to children compared to sedatives administered by the intravenous (IV) route. There is a gap of knowledge, however, regarding the ideal regimen of IN DEX for providing optimal procedural sedation in children undergoing non-painful procedures. There is a large variation in practice using IN DEX, both regarding the dose and the use of adjunct medications. It is also unknown whether regimens should vary based on patient factors such as age. There is no clear evidence to define best practice when using IN DEX to provide sedation in this population to achieve the desired outcomes most relevant to clinicians. The rationale of the proposed investigation is that by conducting an exploratory study to measure clinical outcomes associated with IN DEX, the investigators can begin to identify trends and differences that will lay the foundation for randomized clinical trials to identify the ideal regimen for IN DEX when providing sedation for non-painful procedures. This will then allow the investigators to compare IN DEX, at its best, to other sedatives so that the sedative and regimen associated with the best outcomes relevant to sedation of children undergoing non-painful procedures can be determined. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03220880
Study type	Observational
Source	Columbia University
Contact
Status	Completed
Phase
Start date	September 4, 2018
Completion date	January 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03399019` - Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia	N/A
Recruiting	`NCT04820205` - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children	N/A
Recruiting	`NCT04549623` - End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography	N/A
Recruiting	`NCT04822064` - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation	N/A
Completed	`NCT01001533` - Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation	N/A
Completed	`NCT01527903` - A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit	Phase 4
Completed	`NCT00747721` - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU	Phase 1
Completed	`NCT00158873` - Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects	Phase 4
Terminated	`NCT00205517` - Sedation and Psychopharmacology in Critical Care	N/A
Recruiting	`NCT04096768` - The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation	Phase 3
Active, not recruiting	`NCT05082623` - The Effect of Music on Delirium, Pain, Need of Sedation, Anxiety and Vital Parameters	N/A
Suspended	`NCT03285165` - Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients	Phase 2/Phase 3
Active, not recruiting	`NCT04788589` - Sedation and Ventilator Weaning Protocol in PICU	N/A
Completed	`NCT03425474` - Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy	Phase 3
Recruiting	`NCT06061159` - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction	Phase 4
Completed	`NCT06449365` - Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy	Phase 4
Completed	`NCT02171910` - Doxapram as an Additive to Propofol Sedation in Sedation for ERCP	Phase 4
Completed	`NCT02211118` - Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD	Phase 4
Completed	`NCT01694745` - EUROpean Pain Audit In Neonates	N/A
Completed	`NCT00997113` - Stress During Deep Sedation With Propofol With and Without Alfentanil	Phase 4